Greenwich LifeSciences, Inc. (GLSI)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$10.5M
Cash & Equivalents
$4.7M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$291M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-01 Phase3 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05232916 Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subje... PHASE3 Recruiting 750

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for GLSI.

SEC EDGAR Filings

All SEC filings for Greenwich LifeSciences, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.